Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β
about
Current Research Therapeutic Strategies for Alzheimer's Disease TreatmentTargeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeuticsImmunotherapy for Alzheimer's disease: hoops and hurdlesAdvances in Alzheimer's disease drug developmentProfile of gantenerumab and its potential in the treatment of Alzheimer's diseaseBapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformationCrystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumabImmunotherapeutic approaches for Alzheimer's diseaseAn anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 miceBiomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer.Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases.A novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease.Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.Activity-modulating monoclonal antibodies to the human serine protease HtrA3 provide novel insights into regulating HtrA proteolytic activities.Amyloid-beta: a crucial factor in Alzheimer's disease.Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.Amyloid-ß-directed immunotherapy for Alzheimer's disease.Novel immunological approaches for the treatment of Alzheimer's disease.Tau aggregation and its interplay with amyloid-β.Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system.Advances in recent patent and clinical trial drug development for Alzheimer's disease.Electroacupuncture Reduces Aβ Production and BACE1 Expression in SAMP8 Mice.TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearanceComparing the efficacy and neuroinflammatory potential of three anti-abeta antibodiesAnti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.Advances in the development of vaccines for Alzheimer's disease.Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.Pre-amyloid oligomers budding:a metastatic mechanism of proteotoxicity.Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin.Amyloid-beta immunotherapy: the hope for Alzheimer disease?Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatmentsImmunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the futureOpen questions for Alzheimer's disease immunotherapy.Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease.
P2860
Q26765530-C39022BA-1106-40CA-8B8F-710C9D166112Q26822002-246CBE92-72C5-48D0-81E2-E59E2F9DC22BQ26823877-D4EFED58-8924-4BD0-9DB4-41BFE9A2DCADQ26849352-92BE7E8A-D22B-4A89-8E69-60D3A92166F9Q27027675-60EAAA0C-A729-418D-8974-7D38931F5C8FQ27676409-6E77AFEE-0E48-426F-84C4-FDD83DF53F76Q27684692-92D0FA32-F2C1-4CE1-90A2-508C14294873Q28081278-3EBC1E80-AC6C-4200-B7E7-EA55AD21AAC4Q30316057-D0C8CBEA-94AA-4E29-9677-4A16127432C1Q30651551-54C53C94-6182-4C78-BE4B-E7F99A23B938Q33604583-8696A478-A780-482B-9B5E-649EFDA36E20Q33731321-5B3DFB1F-A8E5-434C-A32E-2CABF6EC548FQ33853280-DE219137-E05D-4FEB-921C-1BEE850979D4Q34091134-273A13D1-C675-4594-963F-C046C4C601F8Q34232310-B8CC3380-562C-4BB9-A822-7920F93C7C70Q34451907-96671403-01EA-4518-8E5C-1D7F4DCE7A58Q34472054-6B02BB91-CF79-4B1C-AB2A-181662169770Q34548700-DCEC7EDC-7EC2-4E11-BB1E-9E9C30D2B857Q34562675-9B052419-736D-4AE6-9DF4-299DC3E15AA9Q35008256-7C792D01-3B4B-460A-AFD5-F1CDDF6F4CC8Q35723422-B38AB802-ABC0-4716-B030-CFEDADDDBAB1Q35738142-7E7C28D6-88B3-4698-B708-F68DC8F28647Q35898132-BC4DB61A-77E0-447D-966A-467DE4C5E4FBQ36073450-083C455A-85A0-45E3-A7FC-2D5EFBC766D4Q36181289-13B1EF4F-9566-4E6E-9CA9-2F133A2A4490Q36269285-6CDFCC80-4E68-4346-AD3B-EFDAE6C6EE11Q36484413-CC716C3D-7C81-4ABC-AA4F-7B31DA15AFC2Q36711795-A908AE69-7A9D-44AC-A347-5CC9F1AEC459Q36850925-3B4BCAAF-8791-497E-840D-78CAF5103B97Q36965988-8B241EF1-FDA7-455A-AF14-30569F86417AQ37312010-4F46E2C1-6258-4E8E-A8CD-A079F06CC550Q37360313-1A3E8857-1D9B-4FCE-AC0A-8251B61A9EA7Q37504954-BE33BB7E-2BD6-4A05-85FD-06DAACA78113Q37519267-F1927564-B1F5-4873-958D-441EE80C0BBAQ37679265-92EE6D75-ABDF-41D8-A58E-03281C7EBD3DQ37730984-6EE35D03-C85F-4C90-AC03-A185F989DCCBQ38079317-4A6C30D1-1881-4DC0-831D-F9936103562BQ38161675-0F291ADD-2B28-4C99-B7B2-30F791F2D4D5Q38176097-C637B659-907C-4D75-99E1-00F42C262DBFQ38219981-D29C4799-BFF8-4F19-B8C2-2CCC856085C7
P2860
Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Gantenerumab: a novel human an ...... ted removal of human amyloid-β
@ast
Gantenerumab: a novel human an ...... ted removal of human amyloid-β
@en
Gantenerumab: a novel human an ...... ted removal of human amyloid-β
@nl
type
label
Gantenerumab: a novel human an ...... ted removal of human amyloid-β
@ast
Gantenerumab: a novel human an ...... ted removal of human amyloid-β
@en
Gantenerumab: a novel human an ...... ted removal of human amyloid-β
@nl
prefLabel
Gantenerumab: a novel human an ...... ted removal of human amyloid-β
@ast
Gantenerumab: a novel human an ...... ted removal of human amyloid-β
@en
Gantenerumab: a novel human an ...... ted removal of human amyloid-β
@nl
P2093
P3181
P356
P1476
Gantenerumab: a novel human an ...... ted removal of human amyloid-β
@en
P2093
Bernd Bohrmann
Christer Nordstedt
Christine Rothe
Francoise Gerber
Frédéric Knoflach
Hansruedi Loetscher
Jürg Messer
Karlheinz Baumann
Krisztina Oroszlan
P3181
P356
10.3233/JAD-2011-110977
P577
2012-01-01T00:00:00Z